Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 janv. 2026 07h05 HE | Source: uniQure Inc.

uniQure Announces Type A Meeting Scheduled with FDA

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
09 janv. 2026 07h02 HE | Source: Ocugen

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
09 janv. 2026 07h00 HE | Source: MapLight Therapeutics, Inc.

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing...
09 janv. 2026 03h13 HE | Source: Alveus Therapeutics Inc

Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme

Financieringen går til fase 2-udvikling af ALV-100, IND-indsendelse af ALV-200 samt fremme af flere udviklingsprogrammer ALV-100, en bifunktionel GIPR-antagonist/GLP-1R-agonist, udviklet til varig...
09 janv. 2026 03h00 HE | Source: Onco3R Therapeutics BV

O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated

Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presented Dosing of the final cohort in the first in human study has been initiated Studies in ulcerative colitis and...
09 janv. 2026 02h30 HE | Source: Allegro NV

Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials

Wallonia Minister of Economy and Employment Pierre-Yves Jeholet will perform opening ceremony on 9 January 2026New cleanroom facility allows production of one million doses per yearRamping up for...
09 janv. 2026 02h00 HE | Source: Zealand Pharma

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy

Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion,...
09 janv. 2026 01h13 HE | Source: Exhale Wellness

THCA Flower Stats 2026: Exhale Wellness Reports Sales Volume and Buyer Usage Trends Across 10 THCA Flower Strains

Charlotte, NC, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The hemp market in 2026 looks very different from just a few years ago. Clearer rules, better lab testing, and stronger buyer awareness have changed...
08 janv. 2026 16h34 HE | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
08 janv. 2026 16h05 HE | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...

Page suivante